Molecular Imaging Corp.

Kenneth C. Frederick was appointed as a director in June 2004. Since January of 2003, Mr. Frederick has been the Vice President, Business Development of Symmorphix, Inc, a company spun-off from Applied Materials, which commercializes materials for advanced electronics, optical displays and electrochemical applications. From May 2001 to January 2003. Mr. Frederick was Vice President, Business Development and Marketing for Picarro a company specializing in the development of laser based technology. From July 1999 to April 2001, Mr. Frederick was Vice President, Corporate Development and Strategy for Stratum Technologies, Inc., a software company specializing in a variety of internet based applications including application for the healthcare industry. Mr. Frederick was nominated by Dragon pursuant to a contractual provision in the Securities Purchase Agreement dated July 12, 2002 between Dragon and the Company.

Dr. Brian D. Ross is a founder and President of Molecular Therapeutics, Inc. He received his doctoral degree from the University of California at Davis. He received a postgraduate Fellowship from the American Brain Tumor and conducted research at the University of Minnesota, Center for Magnetic Resonance Research in cancer biology and imaging. Dr. Ross is also a Professor of Radiology and Biological Chemistry at the University of Michigan where he also serves as a founder and Co-Director of the Center for Molecular Imaging.

Peter S. Conti, M.D., Ph.D. Chairman Dr. Peter Conti, M.D., Ph.D., is Associate Professor of Radiology, Clinical Pharmacy and Biomedical Engineering at the University of Southern California, as well as Director of the USC Positron Imaging Science Center and Clinic. Dr. Conti received his medical degree from Cornell University and completed his residency in Diagnostic Radiology and Fellowship in Nuclear Medicine at the Johns Hopkins Medical Institution. Dr. Conti is Board Certified in both Diagnostic Radiology and Nuclear Medicine. Dr. Conti currently serves on the Board of Directors of the Academy of Molecular Imaging (AMI) and is President Elect of the Society of Nuclear Medicine (SNM). Dr. Conti also serves on a number of committees for the SNM and AMI in government and regulatory affairs, with efforts primarily focused on development of the PET technology and its applications in medicine.

As Director of Molecular Imaging and Biomarkers with RadPharm, Dr. Perlman works with sponsors to develop and implement molecular imaging solutions for drug development clinical trials. He oversees all studies that include PET and other nuclear medicine imaging techniques. Dr. Perlman has more than 15 years clinical experience as a diagnostic radiologist and is board certified in Internal Medicine (1988) and Diagnostic Radiology (1992). Dr. Perlman completed medical imaging training as a Fellow in body imaging at Yale University School of Medicine (1993). He was awarded certification of special competency in Nuclear Medicine in 1993 and achieved certification by the American Society of Nuclear Cardiology in 1995. Dr. Perlman has been involved with medical imaging in the clinical trials area since 1997. He was one of the first Radiologist readers for clinical trials work performed at RadPharm and he has been directly involved as a Radiologist reader/reviewer in over 50 clinical trials. In addition to performing imaging analysis, Dr. Perlmana s responsibilities on these and other projects include protocol review with imaging consultation and imaging charter and imaging manual development. He presents regularly at Investigator meetings as well as international industry meetings on the topic of molecular imaging in clinical trials.